Hepatitis Monthly

Published by: Kowsar

Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis

Li-Hui Long 1 , * , Cai-Qin Xue 1 , Jun-Feng Shi 1 , Juan-Ni Dong 1 and Li Wang 2
Authors Information
1 Department of Pharmacy, the First Affiliated Hospital of Xi’an Medical College, Xi’an, Shaanxi 710077, China
2 Research Division, the First Affiliated Hospital of Xi’an Medical College, Xi’an, Shaanxi 710077, China
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e29052
  • Published Online: July 22, 2015
  • Article Type: Research Article
  • Received: April 11, 2015
  • Revised: May 17, 2015
  • Accepted: May 31, 2015
  • DOI: 10.5812/hepatmon.29052v2

To Cite: Long L, Xue C, Shi J, Dong J, Wang L. et al. Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis, Hepat Mon. 2015 ; 15(7):e29052. doi: 10.5812/hepatmon.29052v2.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Objectives
3. Data Sources
4. Study Selection
5. Data Extraction
6. Results
7. Discussion
Acknowledgements
Footnotes
References
  • 1. Liang GN, Chen LH. Glycyrrhizin injection combined with Danshen injection observe the effect of hepatitis B liver fibrosis. J Tibetan Med. 2010; 31(1): 24-5
  • 2. Alavian SM, Tabatabaei SV, Ghadimi T, Beedrapour F, Kafi-Abad SA, Gharehbaghian A, et al. Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study. Int J Prev Med. 2012; 3(11): 770-5[PubMed]
  • 3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115(2): 209-18[DOI][PubMed]
  • 4. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6): 1655-69[DOI][PubMed]
  • 5. Kim BK, Kim do Y, Park JY, Ahn SH, Chon CY, Kim JK, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010; 30(4): 546-53[DOI][PubMed]
  • 6. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008; 12(4): 733-46[DOI][PubMed]
  • 7. Cao R, Hu XD, Cheng H. Observation on the clinical efficiency of adenosine combine with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. Chin Hosp Pharm J Dis. 2003; 32(6): 481-3
  • 8. Gao Y, Song MZ, Liang CR. Clinical Observation of Ademetionine Combined With Ursodeoxycholic Acid in the Treatment ofChronic Severe Cholestatic Hepatitis. Chin Hosp Pharm Dis. 2013; 14(3): 68-9
  • 9. Joo SS, Kang HC, Won TJ, Lee DI. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1 beta and nitric oxide in rat microglia. Arch Pharm Res. 2003; 26(12): 1067-73[PubMed]
  • 10. Fekaj E, Gjata A, Maxhuni M. The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study. BMC Surg. 2013; 13: 38[DOI][PubMed]
  • 11. Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther. 2013; 38(7): 794-803[DOI][PubMed]
  • 12. Tkacz B, Dworniak D. [Sylimarol in the treatment of acute viral hepatitis]. Wiad Lek. 1983; 36(8): 613-6[PubMed]
  • 13. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013; 32(5): 657-69[DOI][PubMed]
  • 14. Ren BR, Zhao YY, Xu BH, Wu JL, Chen J, Liang CY. Research of silymarin extraction and silibinin purification. Lishizhen Med Materia Med Res. 2012; 23(3): 655-6
  • 15. Feher J, Lengyel G. [Silymarin in the treatment of chronic liver diseases: past and future]. Orv Hetil. 2008; 149(51): 2413-8[DOI][PubMed]
  • 16. Hoffer E, Baum Y, Tabak A, Taitelman U. N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Toxicol Letters. 1996; 84(1): 7-12[DOI]
  • 17. Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology. 1996; 23(5): 1067-72[DOI][PubMed]
  • 18. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep. 1999; 1(1): 42-9[PubMed]
  • 19. Wang N, Shi XF, Guo SH, Zhang DZ, Ren H. [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2008; 16(7): 487-9[PubMed]
  • 20. Xia G. The clinical efficacy observation of acetylcysteine injection on 58 cases of chronic severe hepatitis B. West Chin Med J. 2009; 24(5): 1239-40
  • 21. Shi XF, Guo SH, Wu G, Wang ZY, Ren H, Liu Q. The clinical curative effect observation of acetylcysteine injection on 40 cases of chronic hepatitis B. J Chongqing Med Univ. 2005; 30(1): 115-21
  • 22. Shohrati M, Dermanaki F, Babaei F, Alavian SM. Evaluation of the effects of oral N-acetylcysteine and a placebo in paraclinical and oxidative stress parameters of patients with chronic hepatitis B. Hepat Mon. 2010; 10(2): 95-100[PubMed]
  • 23. Wu G, Guo SH. The Clinic Study of N-Acetylcysteine Injection Therapy to Chronic Hepatitis B. Chongqing Med Univer. 2004; 3: 25-49
  • 24. Wang X, Shen S, Li N, Li Y. [Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010; 35(2): 171-5[DOI][PubMed]
  • 25. Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, et al. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999; 13(9): 1187-93[PubMed]
  • 26. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999; 29(3): 644-7[DOI][PubMed]
  • 27. CAO R, Hu XD, CHENG H, HUANG S, BAI T, GAN H, et al. Observation on the clinical efficiency of adenosine methionine combined with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. Chinese J Hos Pharm. 2013; 6: 19
  • 28. Qureshi H, Mehdi I, Ahmed WU, Alam SE. Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. J Pak Med Assoc. 2006; 56(3): 130-1[PubMed]
  • 29. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011; 54(5): 1011-9[DOI][PubMed]
  • 30. Flisiak R, Prokopowicz D. Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B. Eur J Gastroenterol Hepatol. 1999; 11(11): 1227-30[PubMed]
  • 31. Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepatogastroenterology. 1997; 44(17): 1419-25[PubMed]
  • 32. Gu XB, Yang XJ, Hua Z, Lu ZH, Zhang B, Zhu YF, et al. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B. Chin Med J (Engl). 2012; 125(8): 1434-8[PubMed]
  • 33. Bao FY, Xie J. Silybin phospholipid complex combinated with interferon treating hepatitis B. J Cent Plains Med. 2006; 33(15): 70-1
  • 34. Bao FY, Qiu PY. Analyzing the adjunctive therapy of silibinin phospholipid complex treat chronic hepatitis B in 86 cases. Shandong Med. 2006; 26: 26-31
  • 35. Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int. 2012; 32(6): 977-87[DOI][PubMed]
  • 36. Wang H, Zhao YL, Xu KC. [Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006; 26(11): 978-80[PubMed]
  • 37. Wu Y, Yao DK, Zhu L. [Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012; 32(11): 1477-82[PubMed]
  • 38. Mao ZY, Xiao M, Wu XJ, Tao LG. TanⅡA, Oxymatrine combined therapy on liver function in patients with chronic hepatitis B and liver fibrosis. Pract Clin Med. 2014; 15(2): 21-3
  • 39. Zhou XY, Gao C, Gao XC, Liu XL, Li LH, Wang X. Clinical effects of valsartan on liver fibrosis indexes in patients with alcoholic liver cirrhosis. Chin J Integr Trad Western Med Live Dis. 2014; 24(2): 85-6
  • 40. Gou W, Wang YL. To observe the effect of interferon α-2b combined with silymarin to treat chronic hepatitis B. Clin Hepatol. 2004; 5: 302
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments